3 documents found, page 1 of 1
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José M.; Borrego, Pedro; Cardoso, Fernando; Barroso, HelenaFunding Information: This work was funded by national funds through the FCT-Foundation for Science and Technology, I.P., under the project UIDB/04585/2020, by FCT and Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in Portuguese speaking countries in Africa, project 332821690 and by Ministry of Health, Portugal, project HIV/SAU/0008.11. Publisher Copyright: © 2023 by the authors.; Th...
Evolution of the human immunodeficiency virus type 2 envelope in the first year...
Rocha, Cheila; Calado, Rita; Borrego, Pedro; Marcelino, José M.; Bártolo, Inês; Rosado, Lino; Cavaco-Silva, Patrícia; Gomes, Perpétua; Família, CarlosBackground: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and r...
Baseline susceptibility of primary HIV-2 to entry inhibitors
Borrego, Pedro; Calado, Rita; Marcelino, José M.; Bártolo, Inês; Rocha, Cheila; Cavaco-Silva, Patrícia; Doroana, Manuela; Antunes, FranciscoBackground: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. ...